Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.6 EUR | -7.97% | -8.96% | +80.93% |
01:18pm | TD Cowen Starts NewAmsterdam Pharma With Buy Rating | MT |
May. 09 | Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M | MT |
Evolution of the average Target Price on Frazier Lifesciences Acquisition Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Frazier Lifesciences Acquisition Corporation
Scotiabank | |
RBC Capital Markets | |
Guggenheim | |
Credit Suisse | |
SVB Securities LLC | |
Jefferies & Co. | |
William Blair & Co. |
EPS Revisions
- Stock Market
- Equities
- NAMS Stock
- Consensus Frazier Lifesciences Acquisition Corporation